SELLAS Life Sciences Group, Inc. — Director's Dealing 2013

Jun 18, 2013

SEC Form 4/A — Form 4/A

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2013-06-04

Reporting Person: Hillsberg Sanford (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-06-04	Common Stock	A	9344	—	Acquired	145720	Direct

Footnotes

F1: The shares acquired were issued for the account of the reporting person at a value of $2.60 per share in payment of contingent value rights held by the reporting person. The reporting person's original Form 4 omitted seventeen shares that were acquired by reporting person in payment of the foregoing contingent value rights.